Purpose Identifying patients at high risk of progression and early death among those with
high-tumor-burden follicular lymphoma (FL) is unsatisfactory with current prognostic models …

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular
lymphoma (FL) represent indolent malignancies characterized by multiple episodes of …

Abstract The SAKK 35/10 phase 2 trial, developed by the Swiss Group for Clinical Cancer
Research and the Nordic Lymphoma Group, compared the activity of rituximab vs rituximab …

Background With the introduction of the anti-CD20 antibody rituximab, the outcome of
patients with follicular lymphoma (FL) has greatly improved over the last two decades. First …

Follicular lymphoma (FL) is a heterogeneous disease. For many it is experienced as a
chronic, relapsing, indolent condition with long overall survival (OS). Most people affected …

Background Few studies have evaluated real-world treatment patterns and survival in
follicular lymphoma (FL). This study evaluated these outcomes among newly diagnosed …

Purpose The purpose of this study was to investigate the prognostic significance of total
metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) in patients with follicular …

Mosunetuzumab is a novel bispecific antibody targeting epitopes on CD3 on T cells and
CD20 on B cells with the goal of inducing T-cell mediated elimination of malignant B cells. A …

We examined 83,108 patients with diffuse large B-cell lymphoma (DLBCL) and 43,393
patients with follicular lymphoma (FL) to investigate disparities related to geographic …

Advances in the understanding of FL biology, molecular characteristics and clinical risk
factors are further highlighting the heterogeneity of this disease. Historically used prognostic …